Table 3.
Lifetime Cost-Savings with rtPA Treatment
| Outputs | rtPA | Placebo |
|---|---|---|
| Intracerebral hemorrhage events, N | 6.45 | 1 |
| Total QALYs, N | 392.02 | 310.8 |
| Total cost, $ | 11,778,377 | 12,215,019 |
| Additional intracerebral hemorrhage events, N | 5.45 | |
| QALYs gained, N | 81.22 | |
| Cost-savings, $ | 436,642 | |
| Discounted outcomes | ||
| Total discounted QALYs, N | 335.7 | 266.54 |
| Total discounted cost, $ | 10,806,268 | 11,214,687 |
| QALYs gained, N | 69.17 | |
| Cost-savings, $ | 408,419 | |
| Per patient | ||
| Quality-adjusted months gained, N | 8.3 | |
| Cost-savings, $ | 4084 | |
QALYs indicates quality-adjusted life-years; rtPA, recombinant tissue plasminogen activator.